As we have informed last 3 November 2022 here, Wenger Vieli has also acted as legal and tax advisor to ETH Zurich spin-off LatticeFlow on closing of its USD 12m Series A financing round. The round was
Tags :kevin vangehr
Wenger Vieli has advised NLS Pharmaceutics on a USD 4m private placement and conversion of existing short-term notes of USD 1.53m. NLS Pharmaceutics is a Swiss clinical-stage biopharmaceutical company focused on the discovery and development
Wenger Vieli has advised the shareholders of MENU Technologies on all Swiss legal and tax aspects in a cross-border transaction whereby MENU has become part of the NYSE listed PAR Technology Corp. group. Launched in 2014
